Chronic Obstructive Pulmonary Disease (COPD) History Assessment In SpaiN (CHAIN)
NCT ID: NCT01122758
Last Updated: 2012-11-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
2400 participants
OBSERVATIONAL
2009-12-31
2016-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Currently, there remain gaps in the natural history of patients with COPD. Most data are from analysis of mild COPD patients or smokers, usually measuring only fall in FEV1, and both have significant limitations in design and interpretation.
Studies in more severe patients with COPD have also been conducted mainly by studying lung function, possibly influenced by the recommendations of current guidelines for disease management. In recent years, we have more longitudinal data on changes in exercise capacity, imaging, and biomarkers, among other variables of interest, but our knowledge is yet partial.
The research project CHAIN (COPD Assessment History in Spain): "A Multidimensional Study on the Evolution of Chronic Obstructive Pulmonary Disease (COPD) is a multicenter observational study that will follow prospectively two cohorts: a) a COPD group active or former smokers (COPD cohort) and b) a group of active smokers or former smokers without COPD (control cohort). Both cohorts will be followed up for a period of at least 5 years, with visits every 12 months (and phone controls at least every 6 months). We will try to extend the monitoring of the cohort up to 10 years. CHAIN is supported by the PII of COPD SEPAR
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
COPD cohort
Inclusion criteria:
* Patients ≥ 35 years.
* Diagnosis of COPD (GOLD PBD FEV1/FVC ratio \<0.70).
* Being in a stable phase of disease (8 weeks without exacerbation).
* Cummulative smoking ≥ 10 pack-years.
* Absence of asthma or other chronic respiratory disease that justify the ventilatory disorder (although a history of asthma is not an exclusion criteria);
* Absence of malignancy or very serious comorbidities that would prevent study completion.
Exclusion criteria:
* Patients \<35 years.
* Recent exacerbation (\<8 weeks).
* Not giving written informed consent.
* Presence of asthma or other chronic respiratory disease justifying the ventilatory disorder,
* Diffuse bronchiectasis not associated with COPD.
* Presence of malignancy or very serious comorbidities that would prevent study completion.
* Difficulty to perform appropriate follow-up.
No interventions assigned to this group
Control cohort
Inclusion criteria:
* Patients ≥ 35 years.
* Absence of diagnosis of COPD (GOLD PBD FEV1/FVC ratio \>=0.70).
* Cummulative smoking ≥ 10 pack-years.
* Absence of asthma or other chronic respiratory disease that justify the ventilatory disorder (although a history of asthma is not an exclusion criteria);
* Absence of malignancy or very serious comorbidities that would prevent study completion.
Exclusion criteria:
* Patients \<35 years.
* Not giving written informed consent.
* Presence of asthma or other chronic respiratory disease justifying the ventilatory disorder,
* Diffuse bronchiectasis not associated with COPD.
* Presence of malignancy or very serious comorbidities that would prevent study completion.
* Difficulty to perform appropriate follow-up.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of COPD (GOLD PBD FEV1/FVC ratio \<0.70).
* Being in a stable phase of disease (8 weeks without exacerbation).
* Cummulative smoking ≥ 10 pack-years.
Exclusion Criteria
* Patients \<35 years.
* Recent exacerbation (\<8 weeks).
* Not giving written informed consent.
* Presence of asthma or other chronic respiratory disease justifying the ventilatory disorder,
* Diffuse bronchiectasis not associated with COPD.
* Presence of malignancy or very serious comorbidities that would prevent study completion.
* Difficulty to perform appropriate follow-up.
35 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cimera
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hospital Universitario Nuestra Señora de la Candelaria
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ciro Casanova, MD
Role: PRINCIPAL_INVESTIGATOR
Hospital Nuestra Señora de la Candelaria
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ciro Casanova
Santa Cruz de Tenerife, Canary Islands, Spain
40-50 additional centres throughout Spain
Bunyola, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Ciro Casanova
Role: primary
Joan B Soriano, 724
Role: primary
724 724 724, 724
Role: backup
References
Explore related publications, articles, or registry entries linked to this study.
Casanova C, Gonzalez-Davila E, de Torres JP, Cabrera C, Cosio BG, O'Donnel DE, Martinez-Gonzalez C, Solanes I, Fuster A, Gotera C, Marin A, Amado C, Iscar M, Marin JM, Neder JA, Feu N, Soriano JB, Lopez-Campos JL, Divo M, Peces-Barba G, Celli BR. Lung Diffusing Capacity Improves the Prognostic Validity of the GOLD Spirometric Staging in COPD. Arch Bronconeumol. 2025 May 16:S0300-2896(25)00178-4. doi: 10.1016/j.arbres.2025.05.004. Online ahead of print. English, Spanish.
Casanova C, Gonzalez-Davila E, Martinez-Gonzalez C, Cosio BG, Fuster A, Feu N, Solanes I, Cabrera C, Marin JM, Balcells E, Peces-Barba G, de Torres JP, Marin-Oto M, Calle M, Golpe R, Ojeda E, Divo M, Pinto-Plata V, Amado C, Lopez-Campos JL, Celli BR. Natural Course of the Diffusing Capacity of the Lungs for Carbon Monoxide in COPD: Importance of Sex. Chest. 2021 Aug;160(2):481-490. doi: 10.1016/j.chest.2021.03.069. Epub 2021 Apr 18.
Calle Rubio M, Rodriguez Hermosa JL, de Torres JP, Marin JM, Martinez-Gonzalez C, Fuster A, Cosio BG, Peces-Barba G, Solanes I, Feu-Collado N, Lopez-Campos JL, Casanova C; CHAIN Study Investigators. COPD Clinical Control: predictors and long-term follow-up of the CHAIN cohort. Respir Res. 2021 Feb 4;22(1):36. doi: 10.1186/s12931-021-01633-y.
Soriano JB, Hahsler M, Soriano C, Martinez C, de-Torres JP, Marin JM, de Lucas P, Cosio BG, Fuster A, Casanova C; CHAIN investigators. Temporal transitions in COPD severity stages within the GOLD 2017 classification system. Respir Med. 2018 Sep;142:81-85. doi: 10.1016/j.rmed.2018.07.019. Epub 2018 Aug 3.
Martinez-Gonzalez C, Casanova C, de-Torres JP, Marin JM, de Lucas P, Fuster A, Cosio BG, Calle M, Peces-Barba G, Solanes I, Aguero R, Feu-Collado N, Alfageme I, Romero Plaza A, Balcells E, de Diego A, Marin Royo M, Moreno A, Llunell Casanovas A, Galdiz JB, Golpe R, Lacarcel Bautista C, Cabrera C, Marin A, Soriano JB, Lopez-Campos JL; CHAIN Study Investigators. Changes and Clinical Consequences of Smoking Cessation in Patients With COPD: A Prospective Analysis From the CHAIN Cohort. Chest. 2018 Aug;154(2):274-285. doi: 10.1016/j.chest.2018.02.007. Epub 2018 Feb 22.
Cosio BG, Soriano JB, Lopez-Campos JL, Calle-Rubio M, Soler-Cataluna JJ, de-Torres JP, Marin JM, Martinez-Gonzalez C, de Lucas P, Mir I, Peces-Barba G, Feu-Collado N, Solanes I, Alfageme I, Casanova C; CHAIN Study. Defining the Asthma-COPD Overlap Syndrome in a COPD Cohort. Chest. 2016 Jan;149(1):45-52. doi: 10.1378/chest.15-1055. Epub 2016 Jan 6.
Casanova C, Marin JM, Martinez-Gonzalez C, de Lucas-Ramos P, Mir-Viladrich I, Cosio B, Peces-Barba G, Solanes-Garcia I, Aguero R, Feu-Collado N, Calle-Rubio M, Alfageme I, de Diego-Damia A, Irigaray R, Marin M, Balcells E, Llunell A, Galdiz JB, Golpe R, Lacarcel C, Cabrera C, Marin A, Soriano JB, Lopez-Campos JL, Soler-Cataluna JJ, de-Torres JP; COPD History Assessment in Spain (CHAIN) Cohort. Differential Effect of Modified Medical Research Council Dyspnea, COPD Assessment Test, and Clinical COPD Questionnaire for Symptoms Evaluation Within the New GOLD Staging and Mortality in COPD. Chest. 2015 Jul;148(1):159-168. doi: 10.1378/chest.14-2449.
de Torres JP, Marin JM, Martinez-Gonzalez C, de Lucas-Ramos P, Mir-Viladrich I, Cosio B, Peces-Barba G, Calle-Rubio M, Solanes-Garcia I, Aguero Balbin R, de Diego-Damia A, Feu-Collado N, Alfageme Michavila I, Irigaray R, Balcells E, Llunell Casanovas A, Galdiz Iturri JB, Marin Royo M, Soler-Cataluna JJ, Lopez-Campos JL, Soriano JB, Casanova C; COPD History Assessment in Spain (CHAIN) Cohort*. Clinical application of the COPD assessment test: longitudinal data from the COPD History Assessment in Spain (CHAIN) cohort. Chest. 2014 Jul;146(1):111-122. doi: 10.1378/chest.13-2246.
Related Links
Access external resources that provide additional context or updates about the study.
SEPAR-Sociedad Española de Neumología y Cirugía Torácica
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IB1323/10PI
Identifier Type: OTHER
Identifier Source: secondary_id
CHAIN
Identifier Type: -
Identifier Source: org_study_id